跳至主要内容
临床试验/NCT00157859
NCT00157859已完成不适用

To Evaluate the Efficacy of Chloroquine and SP for Acute Uncomplicated P. Falciparum and the Efficacy of Chloroquine for Acute Uncomplicated P. Vivax in the Timika Region of Papua, Indonesia.

Menzies School of Health Research1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2004年4月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
• 42 day cure rate; corrected for reinfection by PCR genotyping.

研究概览

简要总结

Multidrug resistant strains of P.falciparum and P.vivax are becoming increasingly prevalent in the Asia Pacific rim. To determine the efficacy of locally recommended antimalarial protocols in Papua, Indonesia, consecutive patients presenting to a rural clinic were enrolled into a prospective efficacy study. Patients with uncomplicated falciparum malaria were treated with chloroquine plus sulfadoxine-pyrimethamine and those with vivax malaria with chloroquine monotherapy. Patients failing therapy received unsupervised oral quinine +/- doxycycline for 7 days. Follow-up was continued for 42 days for falciparum malaria and 28 days for vivax malaria.

The study hypothesis was that current recommended antimalarial protocols were no longer effective.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients at least one 1year of age and weighing more than 10kg.
  • -Microscopic confirmation of P. falciparum and /or P.vivax infection (any parasitaemia).
  • -Fever (axillary temperature >37.5oC) or history of fever in the last 48 hours.
  • -Able to participate in the trial and comply with the clinical trial protocol
  • -Written informed consent to participate in trial; verbal consent in presence of literate witness is required for illiterate patients, and written consent from parents/guardian for children below age of consent

排除标准

  • Pregnancy or lactation
  • -Inability to tolerate oral treatment
  • -Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral treatment
  • -Known hypersensitivity or allergy to artemisinin derivatives
  • -Serious underlying disease (cardiac, renal or hepatic)
  • -Parasitaemia >4%

结局指标

主要结局

• 42 day cure rate; corrected for reinfection by PCR genotyping.

• Overall Cure Rate at Day 42

次要结局

  • • Overall day 28 cure rate for P.falciparum. This will allow comparison with previous historical data at this time point.
  • • Parasite reduction. Parasite reduction will be calculated at Days 1, 2 and 3 after initiation of trial treatment as percentage of parasites/uL compared to parasite density before the first dose of treatment.
  • • Proportion of patients with a negative slide at Days 1, 2 and 3
  • • Gametocyte Carriage. Anti-gametocyte activity will be measured by the proportion of patients with a peripheral gametocytaemia between day 7 to day 28.
  • • Early Treatment Failure (ETF)
  • • Late Treatment Failure (LTF)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验